» Articles » PMID: 27721826

Effect on Insulin-Stimulated Release of D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator During Weight Loss in Obese Women with and Without Polycystic Ovary Syndrome

Overview
Publisher Wiley
Specialty Endocrinology
Date 2016 Oct 11
PMID 27721826
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

A deficiency of D-chiro-inositol-inositolphosphoglycan mediator (DCI-IPG) may contribute to insulin resistance in polycystic ovary syndrome (PCOS). Whether the relationship between impaired DCI-IPG release and insulin resistance is specific to PCOS rather than obesity is unknown. We assessed insulin-released DCI-IPG and its relationship to insulin sensitivity at baseline and after weight loss in obese women with and without PCOS. Obese PCOS ( = 16) and normal ( = 15) women underwent 8 weeks of a hypocaloric diet. The Matsuda index, area under the curve DCI-IPG (AUC), AUC, and AUC/AUC were measured during a 2 hr OGTT at baseline and 8 weeks. PCOS women had lower AUC/AUC at baseline and a significant relationship between AUC/AUC and Matsuda index ( = 0.0003), which was not present in controls. Weight loss was similar between PCOS (-4.08 kg) and normal women (-4.29 kg, = 0.6281). Weight loss in PCOS women did not change the relationship between AUC/AUC and Matsuda index ( = 0.0100), and this relationship remained absent in control women. The association between AUC/AUC and insulin sensitivity was only found in PCOS but not in normal women, and this relationship was unaffected by weight loss. DCI and its messenger may contribute to insulin resistance in PCOS independent of obesity.

Citing Articles

The Effect of a Very-Low-Calorie Diet (VLCD) vs. a Moderate Energy Deficit Diet in Obese Women with Polycystic Ovary Syndrome (PCOS)-A Randomised Controlled Trial.

Deshmukh H, Papageorgiou M, Wells L, Akbar S, Strudwick T, Deshmukh K Nutrients. 2023; 15(18).

PMID: 37764656 PMC: 10536436. DOI: 10.3390/nu15183872.


Weight Management Interventions in Women with and without PCOS: A Systematic Review.

Kataoka J, Tassone E, Misso M, Joham A, Stener-Victorin E, Teede H Nutrients. 2017; 9(9).

PMID: 28885578 PMC: 5622756. DOI: 10.3390/nu9090996.

References
1.
Gupta A, Jakubowicz D, Nestler J . Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome. Metab Syndr Relat Disord. 2016; 14(8):391-396. PMC: 5073216. DOI: 10.1089/met.2016.0009. View

2.
Baillargeon J, Iuorno M, Jakubowicz D, Apridonidze T, He N, Nestler J . Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89(1):242-9. DOI: 10.1210/jc.2003-030437. View

3.
Baillargeon J, Diamanti-Kandarakis E, Ostlund Jr R, Apridonidze T, Iuorno M, Nestler J . Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006; 29(2):300-5. DOI: 10.2337/diacare.29.02.06.dc05-1070. View

4.
Knochenhauer E, Key T, Kahsar-Miller M, Waggoner W, Boots L, Azziz R . Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83(9):3078-82. DOI: 10.1210/jcem.83.9.5090. View

5.
Boule N, Weisnagel S, Lakka T, Tremblay A, Bergman R, Rankinen T . Effects of exercise training on glucose homeostasis: the HERITAGE Family Study. Diabetes Care. 2004; 28(1):108-14. DOI: 10.2337/diacare.28.1.108. View